MX356502B - Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer. - Google Patents
Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer.Info
- Publication number
- MX356502B MX356502B MX2017001263A MX2017001263A MX356502B MX 356502 B MX356502 B MX 356502B MX 2017001263 A MX2017001263 A MX 2017001263A MX 2017001263 A MX2017001263 A MX 2017001263A MX 356502 B MX356502 B MX 356502B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- cancer
- prevention
- treatment
- nucleic acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención se refiere a polipéptidos que comprenden o consisten esencialmente en al menos un dominio variable de cadena pesada de un anticuerpo de cadena pesada (VHH) o fragmentos funcionales del mismo, en donde el VHH o fragmento funcional del mismo se une específicamente a una proteína objetivo que está presente en y/o específica para un tumor sólido o una célula cancerosa, por ejemplo HER2. La solicitud proporciona además ácidos nucleicos que codifican para tales polipéptidos; métodos para preparar los polipéptidos; células hospederas que expresan o son capaces de expresar los polipéptidos; composiciones y, en particular, composiciones farmacéuticas que comprenden los polipéptidos, ácidos nucleicos y/o células hospederas. La solicitud proporciona además los polipéptidos, ácidos nucleicos, células hospederas y/o composiciones, para usarse en métodos para la prevención y/o tratamiento de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14178943 | 2014-07-29 | ||
PCT/EP2015/066430 WO2016016021A1 (en) | 2014-07-29 | 2015-07-17 | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017001263A MX2017001263A (es) | 2017-08-10 |
MX356502B true MX356502B (es) | 2018-05-31 |
Family
ID=51225425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017001263A MX356502B (es) | 2014-07-29 | 2015-07-17 | Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9855348B2 (es) |
EP (2) | EP3718574A1 (es) |
JP (1) | JP6289733B2 (es) |
KR (1) | KR101820029B1 (es) |
CN (1) | CN106573983B (es) |
AU (1) | AU2015295687C1 (es) |
BR (1) | BR112017001782A2 (es) |
CA (1) | CA2954359C (es) |
DK (1) | DK3174559T3 (es) |
FI (1) | FI3174559T3 (es) |
MX (1) | MX356502B (es) |
WO (1) | WO2016016021A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3264304B1 (en) * | 2012-02-02 | 2022-03-30 | Brainlab AG | Method for determining an infusion parameter |
US20180036442A1 (en) | 2014-07-29 | 2018-02-08 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response |
JP6917357B2 (ja) * | 2015-07-17 | 2021-08-11 | フレイエ ユニヴェルシテイト ブリュッセルVrije Universiteit Brussel | 癌治療に使用する放射標識抗体断片 |
WO2018178936A1 (en) * | 2017-03-30 | 2018-10-04 | Duke University | Radiolabeled biomolecules and their use |
US11324474B2 (en) * | 2018-09-13 | 2022-05-10 | Canon Medical Systems Corporation | Medical image diagnostic system and radiation dose management apparatus |
EP4178982A1 (en) | 2020-07-13 | 2023-05-17 | Precirix N.V. | Antibody fragment against folr1 |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
ATE370235T1 (de) * | 1994-09-16 | 2007-09-15 | Cancer Res Fund Of Contra Cost | Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
DK0937140T3 (da) | 1996-06-27 | 2008-01-28 | Vlaams Interuniv Inst Biotech | Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft |
BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
EP1141711A1 (en) | 1999-01-05 | 2001-10-10 | Unilever Plc | Binding of antibody fragments to solid supports |
AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
EP1169453A1 (en) | 1999-04-22 | 2002-01-09 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
EP1242460B1 (en) | 1999-11-29 | 2006-10-18 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
ES2331051T3 (es) | 1999-11-29 | 2009-12-21 | Bac Ip B.V. | Inmovilizacion de moleculas de union de antigenos de un dominio. |
DE60138333D1 (de) | 2000-03-14 | 2009-05-28 | Unilever Nv | Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen |
CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
EP1360207B1 (en) | 2000-12-13 | 2011-06-22 | Bac Ip B.V. | Protein arrays of camelid heavy-chain immunoglobulin variable domains |
WO2003025020A1 (fr) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Procede pour creer une banque d'anticorps de chameaux |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
AU2002360068B2 (en) | 2001-12-21 | 2009-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
NZ563471A (en) | 2002-11-08 | 2009-04-30 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
BRPI0316092B8 (pt) | 2002-11-08 | 2021-05-25 | Ablynx Nv | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos |
AU2004204262B2 (en) | 2003-01-10 | 2010-11-04 | Ablynx N.V. | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
WO2010042815A2 (en) * | 2008-10-09 | 2010-04-15 | Duke University | Vhh antibody fragments for use in the detection and treatment of cancer |
WO2011051327A2 (en) * | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
-
2015
- 2015-07-17 AU AU2015295687A patent/AU2015295687C1/en active Active
- 2015-07-17 KR KR1020177005526A patent/KR101820029B1/ko active IP Right Grant
- 2015-07-17 MX MX2017001263A patent/MX356502B/es active IP Right Grant
- 2015-07-17 EP EP20166462.0A patent/EP3718574A1/en active Pending
- 2015-07-17 DK DK15744895.2T patent/DK3174559T3/da active
- 2015-07-17 US US14/802,077 patent/US9855348B2/en active Active
- 2015-07-17 CN CN201580042415.8A patent/CN106573983B/zh active Active
- 2015-07-17 BR BR112017001782A patent/BR112017001782A2/pt active Search and Examination
- 2015-07-17 JP JP2017504726A patent/JP6289733B2/ja active Active
- 2015-07-17 FI FIEP15744895.2T patent/FI3174559T3/fi active
- 2015-07-17 CA CA2954359A patent/CA2954359C/en active Active
- 2015-07-17 EP EP15744895.2A patent/EP3174559B1/en active Active
- 2015-07-17 WO PCT/EP2015/066430 patent/WO2016016021A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
DK3174559T3 (da) | 2022-12-05 |
BR112017001782A2 (pt) | 2017-11-21 |
EP3718574A1 (en) | 2020-10-07 |
EP3174559B1 (en) | 2022-10-19 |
US9855348B2 (en) | 2018-01-02 |
KR20170032463A (ko) | 2017-03-22 |
CN106573983A (zh) | 2017-04-19 |
CA2954359A1 (en) | 2016-02-04 |
AU2015295687C1 (en) | 2019-10-17 |
JP6289733B2 (ja) | 2018-03-07 |
KR101820029B1 (ko) | 2018-02-28 |
CN106573983B (zh) | 2018-05-25 |
EP3174559A1 (en) | 2017-06-07 |
CA2954359C (en) | 2018-09-25 |
MX2017001263A (es) | 2017-08-10 |
WO2016016021A1 (en) | 2016-02-04 |
US20160030606A1 (en) | 2016-02-04 |
AU2015295687A1 (en) | 2017-03-02 |
FI3174559T3 (fi) | 2023-01-13 |
JP2017528435A (ja) | 2017-09-28 |
AU2015295687B2 (en) | 2018-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017001263A (es) | Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer. | |
PH12016502267A1 (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof | |
MX2022001222A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos. | |
CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
MX2017011406A (es) | Terapeuticos de anticuerpo que se unen a tim3. | |
MX2018006072A (es) | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. | |
EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
EP4289484A3 (en) | Anti-ctla-4 antibodies and methods of use thereof | |
MX2018002315A (es) | Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos. | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
PH12016500275B1 (en) | Antibodies | |
GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
EA201892774A1 (ru) | Антитела | |
MA40527A (fr) | Protéines de liaison à l'antigène se liant à wisp5 | |
EA201400964A1 (ru) | Cx3cr1-связывающие полипептиды | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
WO2018069871A3 (en) | Anti-kras binding proteins | |
TW201613971A (en) | Anti-epidermal growth factor receptor (EGFR) antibodies | |
MX2018014366A (es) | Interfaces de proteina. | |
EA201591898A1 (ru) | Антитела, направленные на m-csf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |